-
公开(公告)号：US08679840B2
公开(公告)日：2014-03-25
申请号：US12294453
申请日：2007-03-28
CPC分类号： C12N5/0639 , A61K35/15 , A61K39/0011 , A61K2035/124 , C12N15/85 , C12N2501/02 , C12N2501/23 , C12N2501/2301 , C12N2501/24 , C12N2501/25 , C12N2501/50 , C12N2501/999
摘要： The invention relates to a method for in vitro maturation of at least one immature dendritic cell, comprising stimulating said immature dendritic cell with TNFα, IL- 1β, IFNγ, a TLR7/8 agonist and prostaglandin E2 (PG). Furthermore, the invention relates to a composition comprising these factors as well as to mature dendritic cells produced by a method of the invention.
摘要翻译： 本发明涉及至少一种未成熟树突状细胞体外成熟的方法，包括用TNFα，IL-1和bgr;IFNγ，TLR7 / 8激动剂和前列腺素E2（PG）刺激所述未成熟树突状细胞。 此外，本发明涉及包含这些因素的组合物以及通过本发明的方法生产的成熟树突状细胞。
-
2.发明申请REPERTOIRE OF ALLO-RESTRICTED PEPTIDE-SPECIFIC T CELL RECEPTOR SEQUENCES AND USE THEREOF 有权ALLO-限制性肽特异性T细胞受体序列的替代物及其用途公开(公告)号：US20120128704A1
公开(公告)日：2012-05-24
申请号：US13148653
申请日：2010-02-09
IPC分类号： A61K31/7088 , C07K7/08 , C07K7/06 , A61P35/00 , C07K19/00 , A61K35/26 , A61P37/04 , C12N15/12 , C07K14/725
CPC分类号： C07K14/7051 , C07K14/70503
摘要： The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.
摘要翻译： 本发明涉及包含编码高亲合力，同种异体限制性TCR的核酸序列的成套工具或组合物，其中TCR独立地针对酪氨酸酶抗原，黑色素A抗原和存活蛋白抗原。 本发明还涉及包含至少三组转基因淋巴细胞的试剂盒或组合物，所述转基因淋巴细胞用编码针对所述抗原的TCR的载体转化。 此外，本发明提供药物组合物及其在治疗涉及表达所述肿瘤相关抗原的恶性细胞的疾病中的用途。 本发明还涉及编码识别存活蛋白抗原的TCR的核酸分子，由此编码的TCR和表达所述TCR的T细胞。 此外，本发明公开了一种载体，细胞和编码/含有它们的药物组合物及其在治疗涉及表达存活蛋白的恶性细胞的疾病中的用途。
-
公开(公告)号：US07064190B1
公开(公告)日：2006-06-20
申请号：US09441061
申请日：1999-11-16
申请人： Josef Endl , Peter Stahl , Winfried Albert , Guenther-Gerhard Jung , Dolores J. Schendel , Edgar Meinl , Klaus Dornmair
发明人： Josef Endl , Peter Stahl , Winfried Albert , Guenther-Gerhard Jung , Dolores J. Schendel , Edgar Meinl , Klaus Dornmair
CPC分类号： C07K14/70539 , A61K35/17 , A61K38/19 , C12N9/88 , G01N33/56977 , A61K2300/00
摘要： The invention concerns autoreactive peptides, peptide-MHC complexes, T cell subpopulations that react thereto as well as diagnostic and therapeutic applications of these compounds.
摘要翻译： 本发明涉及自身反应肽，肽-MHC复合物，与其反应的T细胞亚群以及这些化合物的诊断和治疗应用。
-
公开(公告)号：US20100284976A1
公开(公告)日：2010-11-11
申请号：US12294453
申请日：2007-03-28
CPC分类号： C12N5/0639 , A61K35/15 , A61K39/0011 , A61K2035/124 , C12N15/85 , C12N2501/02 , C12N2501/23 , C12N2501/2301 , C12N2501/24 , C12N2501/25 , C12N2501/50 , C12N2501/999
摘要： The invention relates to a method for in vitro maturation of at least one immature dendritic cell, comprising stimulating said immature dendritic cell with TNFα, IL-1β, IFNγ, a TLR7/8 agonist and prostaglandin E2 (PG). Furthermore, the invention relates to a composition comprising said factors as well as to mature dendritic cells produced by the method of the invention.
摘要翻译： 本发明涉及一种用于体外成熟至少一种未成熟树突状细胞的方法，包括用TNFα，IL-1和bgr;IFNγ，TLR7 / 8激动剂和前列腺素E2（PG）刺激所述未成熟树突状细胞。 此外，本发明涉及包含所述因素的组合物以及通过本发明的方法生产的成熟树突状细胞。
-
5.发明授权Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof 有权同种异体限制性肽特异性T细胞受体序列的汇编及其用途公开(公告)号：US09409969B2
公开(公告)日：2016-08-09
申请号：US13148653
申请日：2010-02-09
IPC分类号： C07H21/04 , C07K14/705
CPC分类号： C07K14/7051 , C07K14/70503
摘要： The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.
摘要翻译： 本发明涉及包含编码高亲合力，同种异体限制性TCR的核酸序列的成套工具或组合物，其中TCR独立地针对酪氨酸酶抗原，黑色素A抗原和存活蛋白抗原。 本发明还涉及包含至少三组转基因淋巴细胞的试剂盒或组合物，所述转基因淋巴细胞用编码针对所述抗原的TCR的载体转化。 此外，本发明提供药物组合物及其在治疗涉及表达所述肿瘤相关抗原的恶性细胞的疾病中的用途。 本发明还涉及编码识别存活蛋白抗原的TCR的核酸分子，由此编码的TCR和表达所述TCR的T细胞。 此外，本发明公开了一种载体，细胞和编码/含有它们的药物组合物及其在治疗涉及表达存活蛋白的恶性细胞的疾病中的用途。
-
-
-
-
搜索结果
5 条记录 (耗时 0.013 秒)
